PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

Male Humans Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use Prostatic Neoplasms, Castration-Resistant / drug therapy DNA Repair Signal Transduction
Androgen receptor signalling inhibitor Castration-resistant prostate cancer Metastatic prostate cancer PARP inhibitor

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
09 2023
Historique:
received: 17 03 2023
accepted: 31 03 2023
medline: 14 8 2023
pubmed: 23 4 2023
entrez: 22 04 2023
Statut: ppublish

Résumé

The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.

Identifiants

DOI: 10.1016/j.eururo.2023.03.038 PMID: 37087376
pubmed: 37087376
pii: S0302-2838(23)02716-1
doi: 10.1016/j.eururo.2023.03.038
pii:
doi:

Substances chimiques

Poly(ADP-ribose) Polymerase Inhibitors 0

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-256

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Nick Beije (N)

The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.

Wassim Abida (W)

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Emmanuel S Antonarakis (ES)

Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Elena Castro (E)

Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.

Ronald de Wit (R)

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Karim Fizazi (K)

Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.

Silke Gillessen (S)

Istituto Oncologico della Svizzera Italiana, Ente Ospedaliero Cantonale Bellinzona, Bellinzona, Switzerland.

Maha Hussain (M)

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.

Joaquin Mateo (J)

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Michael J Morris (MJ)

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

David Olmos (D)

Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.

Oliver Sartor (O)

Tulane Cancer Center, Tulane University Medical School, New Orleans, LA, USA.

Adam Sharp (A)

The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.

Christopher J Sweeney (CJ)

South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.

Johann S de Bono (JS)

The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: johann.de-bono@icr.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PARP Inhibitors for Prostate Cancer: Tangled...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Inhibiteurs de poly(ADP-ribose) polymérases › PARP Inhibitors for Prostate Cancer: Tangled...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › PARP Inhibitors for Prostate Cancer: Tangled...
questionsmedicales.fr › Phénomènes génétiques › Réparation de l'ADN › PARP Inhibitors for Prostate Cancer: Tangled...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › PARP Inhibitors for Prostate Cancer: Tangled...